BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19229536)

  • 1. In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B.
    Abu Ajaj K; Graeser R; Fichtner I; Kratz F
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):413-8. PubMed ID: 19229536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
    Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
    Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP).
    Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Tsurumi C; Abu Ajaj K; Warnecke A; Unger C; Saleem T; Kratz F
    Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):14-21. PubMed ID: 21042336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study.
    Shao LH; Liu SP; Hou JX; Zhang YH; Peng CW; Zhong YJ; Liu X; Liu XL; Hong YP; Firestone RA; Li Y
    Cancer; 2012 Jun; 118(11):2986-96. PubMed ID: 22006342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs.
    Abu Ajaj K; Biniossek ML; Kratz F
    Bioconjug Chem; 2009 Feb; 20(2):390-6. PubMed ID: 19199576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
    Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
    Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
    Warnecke A; Fichtner I; Sass G; Kratz F
    Arch Pharm (Weinheim); 2007 Aug; 340(8):389-95. PubMed ID: 17628030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
    Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
    Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of dual-acting prodrugs for circumventing multidrug resistance.
    Abu Ajaj K; Kratz F
    Bioorg Med Chem Lett; 2009 Feb; 19(3):995-1000. PubMed ID: 19131246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study.
    Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Abu Ajaj K; Unger C; Warnecke A; Saleem T; El-Melegy N; Madkor H; Kratz F
    Eur J Cancer; 2010 Dec; 46(18):3434-44. PubMed ID: 20933385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of cathepsin B cleavage albumin-binding SN38 prodrug in breast cancer.
    Lu Y; Huang Y; Jin J; Yu J; Lu W; Zhu S
    Bioorg Chem; 2024 Jun; 147():107370. PubMed ID: 38621338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.
    Kratz F; Warnecke A; Scheuermann K; Stockmar C; Schwab J; Lazar P; Drückes P; Esser N; Drevs J; Rognan D; Bissantz C; Hinderling C; Folkers G; Fichtner I; Unger C
    J Med Chem; 2002 Dec; 45(25):5523-33. PubMed ID: 12459020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
    Abu Ajaj K; Graeser R; Kratz F
    Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin.
    Dubowchik GM; Mosure K; Knipe JO; Firestone RA
    Bioorg Med Chem Lett; 1998 Dec; 8(23):3347-52. PubMed ID: 9873732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix.
    Hochdörffer K; Abu Ajaj K; Schäfer-Obodozie C; Kratz F
    J Med Chem; 2012 Sep; 55(17):7502-15. PubMed ID: 22882004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
    Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
    FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy.
    Shim N; Jeon SI; Yang S; Park JY; Jo M; Kim J; Choi J; Yun WS; Kim J; Lee Y; Shim MK; Kim Y; Kim K
    Biomaterials; 2022 Oct; 289():121806. PubMed ID: 36156411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mamma carcinoma model.
    Kratz F; Roth T; Fichiner I; Schumacher P; Fiebig HH; Unger C
    J Drug Target; 2000; 8(5):305-18. PubMed ID: 11328658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity.
    Dubowchik GM; Firestone RA; Padilla L; Willner D; Hofstead SJ; Mosure K; Knipe JO; Lasch SJ; Trail PA
    Bioconjug Chem; 2002; 13(4):855-69. PubMed ID: 12121142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination.
    Satchi R; Connors TA; Duncan R
    Br J Cancer; 2001 Sep; 85(7):1070-6. PubMed ID: 11592781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.